Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.US-based biotechnology firm Novavax has partnered with Takeda Pharmaceutical to develop, manufacture and commercialise its Covid-19 vaccine candidate, NVX‑CoV2373, in Japan.
Based on Novavax’s recombinant protein nanoparticle technology, the vaccine candidate is a stable, prefusion protein that includes the company’s Matrix‑M adjuvant.
Takeda will receive funding from Japan’s Ministry of Health, Labour and Welfare (MHLW) to support the technology transfer, infrastructure and scale-up of manufacturing.